Remote Ischemic Preconditioning in Septic Patients
Launched by UNIVERSITÄT MÜNSTER · Apr 13, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating a method called remote ischemic preconditioning (RIPC) to see if it can help prevent or lessen acute kidney injury (AKI) in critically ill patients who have sepsis. AKI is a serious condition where the kidneys suddenly can't filter waste from the blood, and it can happen in patients who are very sick. In this study, RIPC involves lightly restricting blood flow to the arm in cycles, which researchers hope will help the kidneys recover better. The effectiveness of this method will be measured using specific urine tests.
To participate, individuals need to be adults aged 18 or older who are critically ill with sepsis and have been on a ventilator for at least 24 hours. They also need to be able to provide written consent. However, people with certain kidney conditions, such as chronic kidney disease or those who are pregnant, cannot take part. If someone joins the trial, they can expect close monitoring by the healthcare team and will contribute to important research that could improve care for future patients with similar conditions.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult patients (age ≥18 years)
- • Critically ill patients with sepsis \< 12 hours
- • Invasive ventilation for at least 24 hours (propofol-free-sedation) and/or vasopressor therapy
- • Unrestricted intensive care for at least 72 hours
- • Written informed consent
- Exclusion Criteria:
- • Pre-existing AKI
- • (Glomerulo-)nephritis, interstitial nephritis, vasculitis
- • Chronic kidney disease with estimated glomerular filtration rate (eGFR) \< 30 ml/min/1.73m²
- • Chronic dialysis dependency
- • Kidney transplant in the last 12 months
- • Oral antidiabetics, sulfonamides or nicorandil
- • Pregnancy or breastfeeding
- • Do-not-reanimate order
- • Participation in another interventional trial involving kidney outcomes within the last 3 months
- • Dependency on the investigator or center
About Universität Münster
Universität Münster is a leading research institution in Germany, renowned for its commitment to advancing knowledge across various scientific disciplines, including medicine and health sciences. The university actively engages in clinical trials to explore innovative treatments and therapies, fostering collaboration between researchers, healthcare professionals, and industry partners. With a focus on improving patient outcomes and contributing to evidence-based medicine, Universität Münster emphasizes rigorous scientific methodologies and ethical standards in its clinical research endeavors. Its multidisciplinary approach ensures a comprehensive understanding of complex health challenges, positioning the university as a pivotal player in the advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Münster, , Germany
Patients applied
Trial Officials
Melanie Meersch-Dini, MD
Principal Investigator
University Hospital Muenster, Dept. of Anesthesiology, Intensive Care Therapy and Pain Medicine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported